L1 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2008 ACS on STN

RN 80500-62-5 REGISTRY

ED Entered STN: 16 Nov 1984

CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 9-(aminomethyl)-4,8-dimethyl- (CA INDEX NAME)

OTHER NAMES:

CN 4'-Aminomethyl-4,5'-dimethylangelicin

CN 4'-Aminomethyl-4,5'-dimethylisopsoralen

MF C14 H13 N O3

CI COM

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

30 REFERENCES IN FILE CA (1907 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

30 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2008 ACS on STN

RN 73459-03-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 5-methyl- (CA INDEX NAME)

OTHER NAMES:

CN 5-Methylangelicin

CN 5-Methylisopsoralen

MF C12 H8 03

CI COM

LC STN Files: BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CHEMLIST, DDFU, DRUGU, EMBASE, MEDLINE, NAPRALERT, RTECS\*, SPECINFO, TOXCENTER, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

53 REFERENCES IN FILE CA (1907 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

53 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2008 ACS on STN

RN 22975-76-4 REGISTRY

ED Entered STN: 16 Nov 1984

#### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

29 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

29 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2008 ACS on STN

RN 5768-44-5 REGISTRY

ED Entered STN: 16 Nov 1984

CN 8H-Furo[3,2-h][1]benzopyran-8-one (CA INDEX NAME)

OTHER NAMES:

CN 2-Propenoic acid, 3-(7-hydroxy-6-benzofuranyl)-,  $\delta$ -lactone

CN 7-Hydroxy-6-benzofuranacrylic acid  $\delta$ -lactone

CN Furo [4', 5': 7, 8] coumarin

CN Pseudoisopsoralen

MF C11 H6 O3

LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, TOXCENTER (\*File contains numerically searchable property data)

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

19 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

19 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2008 ACS on STN

RN 4063-41-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 4,8-dimethyl- (CA INDEX NAME) OTHER CA INDEX NAMES:

CN 5-Benzofuranacrylic acid, 4-hydroxy- $\beta$ ,2-dimethyl-,  $\delta$ -lactone (6CI, 7CI)


OTHER NAMES:

CN 4,8-Dimethylisopsoralen

CN NSC 627260

MF C13 H10 O3

LC STN Files: BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, EMBASE, IPA, MEDLINE, NAPRALERT, RTECS\*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD (\*File contains numerically searchable property data)



# \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

94 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

94 REFERENCES IN FILE CAPLUS (1907 TO DATE)

5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2008 ACS on STN

RN 523-50-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN 2H-Furo[2,3-h]-1-benzopyran-2-one (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Isopsoralen (6CI)

OTHER NAMES:

CN 2-Propenoic acid, 3-(4-hydroxy-5-benzofuranyl)-,  $\delta$ -lactone

CN Angecin

CN Angelicin

CN Angelicin (coumarin derivative)

CN Furo[2,3-h]coumarin

CN Furo [5', 4':7,8] coumarin

CN NSC 404563

DR 39310-13-9

MF C11 H6 O3

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NAPRALERT, RTECS\*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD (\*File contains numerically searchable property data)

### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

755 REFERENCES IN FILE CA (1907 TO DATE)

54 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

759 REFERENCES IN FILE CAPLUS (1907 TO DATE)

34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> s angelicin
T.2
           55 ANGELICIN
=> d 55
L2
     ANSWER 55 OF 55 REGISTRY COPYRIGHT 2008 ACS on STN
     83-46-5 REGISTRY
RN
     Entered STN: 16 Nov 1984
ED
     Stigmast-5-en-3-ol, (3\beta)- (CA INDEX NAME)
CN
OTHER CA INDEX NAMES:
     Nimbosterol (6CI)
CN
     Stigmast-5-en-3\beta-ol (8CI)
OTHER NAMES:
CN
    (-)-\beta-Sitosterol
CN
     (24R)-Ethylcholest-5-en-3\beta-ol
CN
     (24R)-Stigmast-5-en-3\beta-ol
CN
     \alpha-Dihydrofucosterol
CN
     \alpha-Phytosterol
CN
     \beta-Sitosterin
CN
     \beta-Sitosterol
CN
     \Delta 5-Stigmasten-3\beta-ol
     22,23-Dihydrostigmasterol
CN
CN
     24\alpha-Ethylcholesterol
CN
     Angelicin
CN
     Angelicin (steroid)
CN
     Azuprostat
CN
     Betaprost
CN
     Cinchol
CN
     Cupreol
CN
     Harzol
     NSC 18173
CN
CN
     NSC 49083
     NSC 8096
CN
     Prostasal
CN
CN
     Quebrachol
CN
     Rhammol
     Rhamnol
CN
CN
     Sito-Lande
CN
     Sitosterol
CN
     SKF 14463
CN
     Sobatum
CN
     Stigmasterol, 22,23-dihydro-
FS
     STEREOSEARCH
DR
     8003-23-4, 15764-35-9, 76772-70-8, 182512-23-8
MF
     C29 H50 O
CI
                  ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS,
LC
     STN Files:
       BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX,
       CHEMLIST, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB,
       IPA, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, PS, RTECS*, SCISEARCH,
       SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL, USPATOLD,
       VETU
         (*File contains numerically searchable property data)
     Other Sources: DSL**, EINECS**
         (**Enter CHEMLIST File for up-to-date regulatory information)
```

Absolute stereochemistry.

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

13643 REFERENCES IN FILE CA (1907 TO DATE)

245 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

13743 REFERENCES IN FILE CAPLUS (1907 TO DATE)

12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 31.06 31.27

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:58:50 ON 30 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Jul 2008 VOL 149 ISS 5 FILE LAST UPDATED: 29 Jul 2008 (20080729/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l1 <> or isopsoralen?

SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
0.48
31.75

FILE 'REGISTRY' ENTERED AT 17:59:10 ON 30 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

SET SMARTSELECT ON SET COMMAND COMPLETED

SEL L1 1-

L3 SEL L1 1- CHEM: 33 TERMS

SET SMARTSELECT OFF SET COMMAND COMPLETED

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 12.11 43.86

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:59:10 ON 30 JUL 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

S L3 OR ISOPSORALEN?

236 ISOPSORALEN?

L5 1087 L4 OR ISOPSORALEN?

=> s 15 or furocoumarin or angecin or nsc 404563

1351 FUROCOUMARIN

1833 FUROCOUMARINS

2296 FUROCOUMARIN

(FUROCOUMARIN OR FUROCOUMARINS)

1 ANGECIN

4254 NSC

778 NSCS

4751 NSC

(NSC OR NSCS)

0 404563

0 NSC 404563

(NSC(W) 404563)

L6 2941 L5 OR FUROCOUMARIN OR ANGECIN OR NSC 404563

=> s thalassaemia or thalassemia or e4, e5 or thalassemic or thalassaemic

191 THALASSAEMIA

11 THALASSAEMIAS

202 THALASSAEMIA

(THALASSAEMIA OR THALASSAEMIAS)

5965 THALASSEMIA

399 THALASSEMIAS

6023 THALASSEMIA

(THALASSEMIA OR THALASSEMIAS)

10046 "ANEMIA (DISEASE)"/CT

4543 THALASSEMIA/CT

1126 THALASSEMIC

69 THALASSEMICS

1163 THALASSEMIC

(THALASSEMIC OR THALASSEMICS)

17 THALASSAEMIC

1 THALASSAEMICS

18 THALASSAEMIC

(THALASSAEMIC OR THALASSAEMICS)

L7 15878 THALASSAEMIA OR THALASSEMIA OR ("ANEMIA (DISEASE)"/CT OR THALAS

## SEMIA/CT) OR THALASSEMIC OR THALASSAEMIC

=> s 16 and 17

10 L6 AND L7

=> focus

PROCESSING COMPLETED FOR L8 10 FOCUS L8 1-

=> d ibib abs 1-10

ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN T.9

ACCESSION NUMBER: 2004:120717 CAPLUS

DOCUMENT NUMBER: 140:157454

Use of angelicin and its structural analogs TITLE:

for the treatment of thalassemia

Bianchi, Nicoletta; Borgatti, Monica; Gambari, Roberto; Lampronti, Ilaria INVENTOR(S):

Universita' Degli Studi Di Ferrara, Italy; PATENT ASSIGNEE(S):

Associazione Veneta Per La Lotta Alla Talassemia

SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA:	PATENT NO.					KIND DATE			APPLICATION NO.						DATE				
WO	2004	0127	29		A1		20040212			WO 2003-IB3462						20030730			
	W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,		
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,		
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	NZ,	OM,		
		PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	TJ,	TM,	TN,		
		TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	zw					
	R₩:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,		
		KG,	ΚΖ,	MD,	RU,	ΤJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,		
		FI,	FR,	GB,	GR,	HU,	IE,	ΙΤ,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,		
		BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	G₩,	ML,	MR,	NE,	SN,	TD,	TG		
AU	2003	2494	72		A1		2004	0223		AU 2003-249472					20030730				
EP	1545	506			A1		2005	0629		EP 2	003-	7665	80		2	0030	730		
EP	1545	506			В1		2008	0220											
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,		
							RO,												
AT	3865	13			T		2008	0315		AT 2	003-	7665	80		2	0030	730		
US	2006	0111	433		A1		2006	0525		US 2	005-	5227	37		2	0051	012		
PRIORIT	Y APP	LN.	INFO	.:						IT 2	002-	TO68	4	i	A 20020731				
										WO 2	003-	IB34	62	W 20030730					

AB The invention describes the use of angelicin and its structural analogs for the preparation of a medicament for the therapeutic treatment of beta-thalassemia. A structural analog which is particularly preferred for this purpose is bergapten.

ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

2008:177329 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 148:345420

TITLE: Structure and biological activity of

furocoumarins

Gambari, Roberto; Lampronti, Ilaria; Bianchi, AUTHOR(S):

Nicoletta; Zuccato, Cristina; Viola, Giampietro; Vedaldi, Daniela; Dall'Acqua, Francesco

CORPORATE SOURCE:  ${\tt ER-GenTech,\ Department\ of\ Biochemistry\ and\ Molecular}$ 

Biology, Section of Molecular Biology, University of Ferrara, Ferrara, 44100, Italy

SOURCE: Topics in Heterocyclic Chemistry (2007), 9 (Bioactive Heterocycles III), 265-276 CODEN: THCOA6; ISSN: 1861-9282

PUBLISHER: Springer GmbH

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

In this review we summarize the structure and biol. effects of linear and angular psoralens. These compds. exhibit very interesting biol. effects on cell cycle, apoptosis and differentiation. These mols. should be considered as promising drugs in the therapy of several diseases, including psoriasis, mycosis fungoides, cancer. In addition, pre-clin. data demonstrate a possible employment of these mols. for the treatment of  $\beta$ - thalassemia.

ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:786184 CAPLUS

DOCUMENT NUMBER: 140:157093

TITLE: Accumulation of  $\gamma$ -globin mRNA in human erythroid

cells treated with angelicin

Lampronti, Ilaria; Bianchi, Nicoletta; Borgatti, AUTHOR(S):

Monica; Fibach, Eitan; Prus, Eugenia; Gambari, Roberto

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology,

University of Ferrara, Ferrara, Italy

SOURCE: European Journal of Haematology (2003), 71(3), 189-195

CODEN: EJHAEC; ISSN: 0902-4441

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

The aim of the present study was to determine whether angelicin is able to increase the expression of  $\gamma$ -globin genes in human erythroid cells. Angelicin is structurally related to psoralens, a well-known chemical class of photosensitizers used for their antiproliferative activity in treatment of different skin diseases (i.e., psoriasis and vitiligo). To verify the activity of angelicin, we employed two exptl. cell systems, the human leukemic K562 cell line and the two-phase liquid culture of human erythroid progenitors isolated from normal donors. The results of our investigation suggest that angelicin, compared with cytosine arabinoside, mithramycin and cisplatin, is a powerful inducer of erythroid differentiation and  $\gamma\text{-globin}$  mRNA accumulation of human leukemia K562 cells. In addition, when normal human erythroid precursors were cultured in the presence of angelicin, increases of  $\gamma$ -globin mRNA accumulation and fetal Hb (HbF) production, even higher than those obtained using hydroxyurea, were detected. These results could have practical relevance, as pharmacol.-mediated regulation of the expression of human  $\gamma$ -globin genes, leading to HbF induction, is considered a potential therapeutic approach in hematol. disorders, including  $\beta$ - thalassemia and sickle cell anemia.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:158569 CAPLUS

DOCUMENT NUMBER: 148:397073

Induction of  $\gamma$ -globin mRNA, erythroid TITLE:

differentiation and apoptosis in UVA-irradiated human

erythroid cells in the presence of

furocoumarin derivatives

AUTHOR(S): Viola, Giampietro; Vedaldi, Daniela; Dall'Acqua,

Francesco; Fortunato, Elena; Basso, Giuseppe; Bianchi,

Nicoletta; Zuccato, Cristina; Borgatti, Monica;

Lampronti, Ilaria; Gambari, Roberto

Department of Pharmaceutical Sciences, University of CORPORATE SOURCE:

Padova, Padua, 35131, Italy

Biochemical Pharmacology (2008), 75(4), 810-825 CODEN: BCPCA6; ISSN: 0006-2952 SOURCE:

PUBLISHER: Elsevier B.V. DOCUMENT TYPE: Journal LANGUAGE: English

Psoralens, also known as furocoumarins, are a class of photosensitizers largely used in the therapy of various skin diseases. In this study we have evaluated the combined effects of UVA irradiation and furocoumarins derivs. on (a) erythroid differentiation and apoptosis of human leukemia K562 cells and (b) globin gene expression in cultures of human erythroid progenitors derived from the peripheral blood. To prove the activity of a series of linear and angular furocoumarins derivs., we employed the human leukemia K562 cell line and the two-phase liquid culture procedure for growing erythroid progenitors. Quant. real-time reverse transcription polymerase-chain assay (Q-RT-PCR) was employed for quantification of the accumulation of globin mRNAs. The results obtained demonstrate that both linear and angular furocoumarins are strong inducers of erythroid differentiation of K562 cells. From a preliminary screening, we have selected two derivs., 5-methoxypsoralen (5-MOP) and trimethylangelicin (TMA), for which we have investigated their mechanism of action. The cell cycle anal. showed that these derivs. induce, after irradiation, a cell cycle

arrest in the G2/M phase, followed by apoptosis. Mitochondrial depolarization and caspases activation seem to be involved in the mechanism of cell death. In erythroid precursor cells, psoralens in combination with UVA irradiation, stimulate at very low concns. a preferential

increase of  $\gamma$ -globin mRNA. Altogether, these data suggest that psoralen derivs. warrant further evaluation as potential therapeutic drugs in  $\beta$ - thalassemia and sickle cell anemia.

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:183297 CAPLUS

DOCUMENT NUMBER: 108:183297

ORIGINAL REFERENCE NO.: 108:30033a,30036a

TITLE: Method and kit for rapid detection of nucleic acid

sequences in a sample by labeling the sample

INVENTOR(S): Dattagupta, Nanibhushan; Rae, Peter M. M.; Rabin,

Daniel U.; Huguenel, Edward D.

PATENT ASSIGNEE(S): Molecular Diagnostics, Inc., USA

SOURCE: Eur. Pat. Appl., 29 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 235726	A2	19870909	EP 1987-102577		19870224
EP 235726	A3	19890510			
EP 235726	B1	19930519			
R: AT, BE, (	CH, DE, ES	, FR, GB,	GR, IT, LI, NL, SE		
NO 8700613	A	19870907	NO 1987-613		19870217
CA 1295535	С	19920211	CA 1987-530235		19870220
AT 89606	T	19930615	AT 1987-102577		19870224
FI 8700923	A	19870906	FI 1987-923		19870303
DK 8701120	A	19870906	DK 1987-1120		19870304
ZA 8701554	A	19871230	ZA 1987-1554		19870304
AU 8769723	A	19870910	AU 1987-69723		19870305
AU 599083	B2	19900712			
JP 62265999	A	19871118	JP 1987-51169		19870305
CA 1314794	С	19930323	CA 1987-553597		19871204
US 5348855	A	19940920	US 1991-772625		19911004
PRIORITY APPLN. INFO.	:		US 1986-836378	A	19860305
			US 1986-943006	A	19861229

EP 1987-102577 A 19870224 US 1987-24643 A 19870311

AB A method for detecting ≥1 microorganism or polynucleotide sequence from eukaryotic sources in a nucleic acid-containing sample comprises (a) labeling the nucleic acids in the test sample; (b) immobilizing an oligonucleotide or a single-stranded nucleic acid of ≥1 known microorganism or sequences from eukaryotic sources to make  $\geq 1$ probe; (c) contacting, under hybridization conditions, the labeled single-stranded sample nucleic acid and the immobilized probe to form a hybridized labeled nucleic acid; and (d) assaying for the hybridized nucleic acid by detecting the label. A kit comprises immobilized probe, reagent for labeling the sample nucleic acids, reagent for denaturing the nucleic acids, and hybridization reagents. Urine samples from patients with suspected urinary tract infections were centrifuged, treated with NaOH, and heated to  $100^{\circ}$  to lyse the cells. The suspension was diluted with Na borate buffer and neutralized to pH 7. Biotin-PEGangelicin (preparation described) was added and the mixture was irradiated with a long-wavelength UV lamp for 15 min. The irradiated sample was added to hybridization reagents and hybridization was conducted with probes (whole genomic DNA of Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, etc.) immobilized onto nitrocellulose paper. Hybridization was detected by an immunogold assay with affinity-isolated goat anti-biotin antibody and Ag enhancement. A spot of human DNA was also present on the paper for detection of leukocytes.

ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

2008:850726 CAPLUS ACCESSION NUMBER:

TITLE: Furocoumarins photolysis products induce differentiation of human erythroid cells

Viola, Giampietro; Vedaldi, Daniela; Dall'Acqua, AUTHOR(S):

Francesco; Lampronti, Ilaria; Bianchi, Nicoletta; Zuccato, Cristina; Borgatti, Monica; Gambari, Roberto

Department of Pharmaceutical Sciences, University of CORPORATE SOURCE:

Padova, Via Marzolo 5, University of Padova, Padua,

35131, Italy

SOURCE: Journal of Photochemistry and Photobiology, B: Biology

(2008), 92(1), 24-28 CODEN: JPPBEG; ISSN: 1011-1344

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

Psoralens, also known as furocoumarins, are a well-known class AB of photosensitizers largely used in the therapy of various skin disease. In this study we have evaluated the effects of crude pre-irradiated solns. of furocoumarins derivs. on (a) erythroid differentiation and apoptosis of human leukemic K562 cells and (b) Hb synthesis in cultures of human erythroid progenitors derived from the peripheral blood. To prove the activity of a mixture of photoproducts generated by UVA irradiation of

the

three psoralen derivs. 5-methoxypsoralen (5-MOP) 8-methoxypsoralen (8-MOP), and angelicin (ANG), we employed the human leukemic K562 cell line and the two-phase liquid culture procedure for growing erythroid progenitors. The results obtained demonstrate that pre-irradiated solns. of psoralen derivs. significantly induce erythroid differentiation of K562 cells irresp. of the type of derivative used, suggesting that the active photoproduct(s) share a common structure. Interestingly, solns. of psoralens irradiated in anaerobic conditions do not exhibits erythroid inducing ability, indicating that the effect is mostly due to photooxidized psoralen products. In erythroid precursor cells, psoralens photolysis products stimulates at low concns. an increase of Hb A and Hb F. Altogether, these data suggest that photoproducts of psoralen warrant further evaluation as potential therapeutic drugs in  $\beta$ - thalassemia and sickle cell anemia.

DOCUMENT NUMBER: 108:164418

ORIGINAL REFERENCE NO.: 108:26955a,26958a

TITLE: Preparation and use of

Preparation and use of reagents for a single probe solution-phase hybridization assay for the detection of a nucleotide sequence, and kits containing the

reagents

INVENTOR(S):
Dattagupta, Nanibhushan

PATENT ASSIGNEE(S): Molecular Diagnostics, Inc., USA

SOURCE: Eur. Pat. Appl., 50 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

an

PATENT 1	PATENT NO.			APPLICATION NO.		DATE
EP 2378 EP 2378	-	A2 A3	19870923 19910116	EP 1987-102576		19870224
EP 2378. R:	-	B1 CH, DE,	19930113 ES, FR, GB,	GR, IT, LI, NL, SE		
CA 1290	664	С	19911015	CA 1986-526423		19861229
NO 8700	512	A	19870907	NO 1987-612		19870217
AT 8457	4	T	19930115	AT 1987-102576		19870224
ES 2053	457	Т3	19940801	ES 1987-102576		19870224
FI 8700	922	A	19870906	FI 1987-922		19870303
DK 8701	121	A	19870906	DK 1987-1121		19870304
ZA 8701	555	A	19871125	ZA 1987-1555		19870304
AU 8769	724	A	19870910	AU 1987-69724		19870305
JP 6228	2599	A	19871208	JP 1987-51170		19870305
US 4968	502	A	19901106	US 1989-442423		19891121
PRIORITY APP	LN. INFO.	:		US 1986-836360	A	19860305
				US 1986-927613	A	19861114
				EP 1987-102576	A	19870224

AB A particular nucleic acid sequence of clin. significance can be rapidly determined by a homogeneous single-probe hybridization assay. The test sample

containing chemical modified nucleic acids having a label (or a reactive site)

will hybridize with a nucleic acid probe carrying a reactive site (or a label). The hybrids are selectively separated out by contacting then with

immobilized reactive partner. The hybrid and the reactive partner form a stable bond, and the extent of hybridization can be measured by determining the

label in the immobilized fraction or a decrease in the label in the remaining solution. The homogeneous single-probe hybridization method, as described above was employed to detect the presence of  $\alpha-$  thalassemia in prenatal samples (no data). The sample nucleic acid and the probe were labeled photochem. With biotin and  $4\!$ '-aminomethyl-4,5' di-Me angelicin, resp.

L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:550062 CAPLUS

DOCUMENT NUMBER: 111:150062

ORIGINAL REFERENCE NO.: 111:24949a,24952a

TITLE: Nucleic acid sequence determination by hybridization

probe and its use in the identification of

microorganisms and prokaryotic or eukaryotic DNA and

in clinical diagnosis

INVENTOR(S): Dattagupta, Nanibhushan; Rabin, Daniel; Rae, Peter;

Huguenel, Edward

PATENT ASSIGNEE(S): Molecular Diagnostics, Inc., USA

SOURCE: Eur. Pat. Appl., 31 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 281927 EP 281927 EP 281927	A2 A3 B1	19880914 19910417 19950628	EP 1988-103221	19880303
R: CH, DE, ES		G, GR, IT,	LI, NL, SE	4.0.0.74.0.0.4
CA 1314794 AU 8812151	C A	19930323 19880915	CA 1987-553597 AU 1988-12151	19871204 19880223
AU 601021 JP 63313598	B2 A	19900830 19881221	JP 1988-56517	19880311
US 5348855 PRIORITY APPLN. INFO.:	A	19940920	US 1991-772625 US 1987-24643	19911004 A 19870311
			US 1986-836378 US 1986-943006	B2 19860305 A 19861229

AB A method for the detection and identification of microorganisms or nucleic acid sequences in a test sample comprises: (1) labeling the nucleic acids in the sample, (2) contacting the labeled nucleic acids with  $\geq 1$  immobilized probe containing complementary nucleic acids under hybridization conditions, and (3) detecting the label. The labeling compound 4'-biotinyl-PEG-4,5'-dimethylangelicin (I) was prepared In  $\alpha-$  thalassemia diagnosis, a test sample containing nucleic acid was dissolved in 10 mM borate buffer (pH 8.0) to a final concentration of .apprx.20

 $\mu g/\text{mL.}$  To the nucleic acid solution I in aqueous solution was added to a final

concentration of 10  $\mu\text{g/mL.}$  The mixture was then irradiated at long wavelength

irradiation for .apprx.60 min using a black ray UVL  $56\ \text{lamp}$ . The labeled test

sample was hybridized with probes immobilized on a nitrocellulose strip at  $42^{\circ}$  for 16 h and the biotinylated hybrids were detected by a colorimetric or chemiluminescence method.

L9 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:638196 CAPLUS

DOCUMENT NUMBER: 137:165813

TITLE: Methods and compositions for analyzing nucleic acids

INVENTOR(S):
Dattagupta, Nanibhushan

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIND		DATE			APPLICATION NO.						DATE		
US 20020115074 A1			_	20020822			US 2	001-	7910	30		20010220					
US 6620	586			В2		2003	0916										
WO 2002070749			A2		20020912			WO 2002-US3782						20020205			
WO 2002	0707	49		A3		2007	0531										
W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	
	UA,	UG,	UZ,	VN,	YU,	ZA,	ZW										
RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	CH,	
						FR,											
	BF,	вJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	
	AP,	EA,	AM,	AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM,	EP,	OA			·	

AU 2002311759 A1 20020919 AU 2002-311759 20020205 US 20030211532 20031113 US 2003-458606 A1 20030609 PRIORITY APPLN. INFO.: US 2001-791030 A 20010220 WO 2002-US3782 W 20020205

The present invention relates to methods and compns. for analyzing nucleic acids. In particular, the invention provides for methods and combinations for analyzing nucleic acids in a plurality of samples using a plurality of detectably different signature labels and a probe that is hybridizable to each of the target nucleic acids. The invention also provides for a method for quantifying a nucleic acid by analyzing the amount of a label, e.g., a photoactivatable label, attached to the target nucleic acid.

ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN 1.9

ACCESSION NUMBER: 1992:56598 CAPLUS

DOCUMENT NUMBER: 116:56598

ORIGINAL REFERENCE NO.: 116:9751a,9754a

TITLE: Defective DNA endonuclease activities in Fanconi's

anemia cells, complementation groups A and B

AUTHOR(S): Lambert, Muriel W.; Tsongalis, Gregory J.; Lambert, W.

Clark; Hang, Bo; Parrish, David D.

New Jersey Med. Sch., UMDNJ, Newark, NJ, 07103, USA CORPORATE SOURCE:

Mutation Research, DNA Repair (1991), 273(1), 57-71 SOURCE:

CODEN: MRDRBE; ISSN: 0921-8777

DOCUMENT TYPE: Journal LANGUAGE: English

Cells from patients with the inherited disorder, Fanconi's anemia (FA), were analyzed for endonucleases which recognize DNA interstrand cross-links and monoadducts produced by psoralen plus UVA irradiation Two chromatin-associated DNA endonuclease activities, defective in their ability to incise DNA-containing adducts produced by psoralen plus UVA light, have been identified and isolated in nuclei of FA cells. In FA complementation group A (FA-A) cells, one endonuclease activity, pI 4.6, which recognizes psoralen intercalation and interstrand cross-links, has 25% of the activity of the normal human endonuclease, pI 4.6, on 8-methoxypsoralen (8-MOP) plus UVA-damaged DNA. In FA complementation group B (FA-B) cells, a second endonuclease activity, pI 7.6, which recognizes psoralen monoadducts, has 50% and 55% of the activity, resp., of the corresponding normal endonuclease on 8-MOP or angelicin plus UVA-damaged DNA. Kinetic anal. reveals that both the FA-A endonuclease activity, pI 4.6, and the FA-B endonuclease activity, pI 7.6, have decreased affinity for psoralen plus UVA-damaged DNA. Both the normal and FA endonucleases showed .apprx.2.5-fold increase in activity on psoralen plus UVA-damaged reconstituted nucleosomal DNA compared to damaged non-nucleosomal DNA, indicating that interaction of these FA endonucleases with nucleosomal DNA is not impaired. These deficiencies in two nuclear DNA endonuclease activities from FA-A nd FA-B cells correlate with decreased levels of unscheduled DNA synthesis (UDS), in response to 8-MOP or angelicin plus UVA irradiation, in these cells in culture.

=> d his

(FILE 'HOME' ENTERED AT 17:55:08 ON 30 JUL 2008)

FILE 'REGISTRY' ENTERED AT 17:55:28 ON 30 JUL 2008

8 S ISOPSORALEN

L1 L255 S ANGELICIN

FILE 'CAPLUS' ENTERED AT 17:58:50 ON 30 JUL 2008

FILE 'REGISTRY' ENTERED AT 17:59:10 ON 30 JUL 2008


SET SMARTSELECT ON

L3 SEL L1 1- CHEM: 33 TERMS

SET SMARTSELECT OFF


FILE 'CAPLUS' ENTERED AT 17:59:10 ON 30 JUL 2008

```
L4
           1080 S L3
L5
            1087 S L4 OR ISOPSORALEN?
L6
            2941 S L5 OR FUROCOUMARIN OR ANGECIN OR NSC 404563
                 E THALASSEMIA+ALL/CT
L7
           15878 S THALASSAEMIA OR THALASSEMIA OR E4, E5 OR THALASSEMIC OR THALA
L8
              10 S L6 AND L7
              10 FOCUS L8 1-
L9
=> d ibib abs hitstr 1-10
     ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:
                           2004:120717 CAPLUS
DOCUMENT NUMBER:
                           140:157454
TITLE:
                           Use of angelicin and its structural analogs
                           for the treatment of thalassemia
INVENTOR(S):
                           Bianchi, Nicoletta; Borgatti, Monica; Gambari,
                           Roberto; Lampronti, Ilaria
                           Universita' Degli Studi Di Ferrara, Italy;
PATENT ASSIGNEE(S):
                           Associazione Veneta Per La Lotta Alla Talassemia
                           PCT Int. Appl., 18 pp.
SOURCE:
                           CODEN: PIXXD2
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                                                                       DATE
     PATENT NO.
                           KIND
                                 DATE
                                               APPLICATION NO.
                                  20040212 WO 2003-IB3462
     WO 2004012729
                           A1
                                                                        20030730
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
              PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
              TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003249472
                                   20040223
                                             AU 2003-249472
                                                                         20030730
                            A1
                                               EP 2003-766580
     EP 1545506
                            Α1
                                   20050629
                                                                         20030730
     EP 1545506
                                  20080220
                            В1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     AT 386513
                            Τ
                                   20080315
                                               AT 2003-766580
                                                                         20030730
     US 20060111433
                            Α1
                                  20060525
                                               US 2005-522737
                                                                         20051012
                                                IT 2002-T0684
PRIORITY APPLN. INFO.:
                                                                     A 20020731
                                               WO 2003-IB3462
                                                                    W 20030730
     The invention describes the use of angelicin and its structural
AΒ
     analogs for the preparation of a medicament for the therapeutic treatment of
     beta-thalassemia. A structural analog which is particularly
     preferred for this purpose is bergapten.
ΙT
     523-50-2, Angelicin 523-50-2D,
     Angelicin, analogs
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
         (angelicin and structural analogs for treatment of
        thalassemia)
RN
     523-50-2 CAPLUS
CN
     2H-Furo[2,3-h]-1-benzopyran-2-one (CA INDEX NAME)
```



RN 523-50-2 CAPLUS

CN 2H-Furo[2,3-h]-1-benzopyran-2-one (CA INDEX NAME)



L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:177329 CAPLUS

DOCUMENT NUMBER: 148:345420

TITLE: Structure and biological activity of

furocoumarins

AUTHOR(S): Gambari, Roberto; Lampronti, Ilaria; Bianchi,

Nicoletta; Zuccato, Cristina; Viola, Giampietro;

Vedaldi, Daniela; Dall'Acqua, Francesco

CORPORATE SOURCE: ER-GenTech, Department of Biochemistry and Molecular

Biology, Section of Molecular Biology, University of

Ferrara, Ferrara, 44100, Italy

SOURCE: Topics in Heterocyclic Chemistry (2007), 9 (Bioactive

Heterocycles III), 265-276 CODEN: THCOA6; ISSN: 1861-9282

PUBLISHER: Springer GmbH

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB In this review we summarize the structure and biol. effects of linear and angular psoralens. These compds. exhibit very interesting biol. effects on cell cycle, apoptosis and differentiation. These mols. should be considered as promising drugs in the therapy of several diseases, including psoriasis, mycosis fungoides, cancer. In addition, pre-clin. data demonstrate a possible employment of these mols. for the treatment of  $\beta-$  thalassemia.

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:786184 CAPLUS

DOCUMENT NUMBER: 140:157093

TITLE: Accumulation of  $\gamma$ -globin mRNA in human erythroid

cells treated with angelicin

AUTHOR(S): Lampronti, Ilaria; Bianchi, Nicoletta; Borgatti,

Monica; Fibach, Eitan; Prus, Eugenia; Gambari, Roberto

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology,

University of Ferrara, Ferrara, Italy

SOURCE: European Journal of Haematology (2003), 71(3), 189-195

CODEN: EJHAEC; ISSN: 0902-4441

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB The aim of the present study was to determine whether angelicin is able to increase the expression of  $\gamma$ -globin genes in human erythroid cells. Angelicin is structurally related to psoralens, a

cells. Angelicin is structurally related to psoralens, a well-known chemical class of photosensitizers used for their

antiproliferative activity in treatment of different skin diseases (i.e.,

psoriasis and vitiligo). To verify the activity of angelicin,

we employed two exptl. cell systems, the human leukemic K562 cell line and the two-phase liquid culture of human erythroid progenitors isolated from

The results of our investigation suggest that normal donors. angelicin, compared with cytosine arabinoside, mithramycin and cisplatin, is a powerful inducer of erythroid differentiation and  $\gamma$ -globin mRNA accumulation of human leukemia K562 cells. In addition, when normal human erythroid precursors were cultured in the presence of angelicin, increases of  $\gamma$ -globin mRNA accumulation and fetal Hb (HbF) production, even higher than those obtained using hydroxyurea, were detected. These results could have practical relevance, as pharmacol.-mediated regulation of the expression of human  $\gamma$ -globin genes, leading to HbF induction, is considered a potential therapeutic approach in hematol. disorders, including  $\beta$ - thalassemia and sickle cell anemia.


ΤТ 523-50-2, Angelicin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(angelicin effect on  $\gamma$ -globin mRNA accumulation in human erythroid cells)

523-50-2 CAPLUS RN

2H-Furo[2,3-h]-1-benzopyran-2-one (CA INDEX NAME) CN



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:158569 CAPLUS

DOCUMENT NUMBER: 148:397073

Induction of  $\gamma$ -globin mRNA, erythroid TITLE:

differentiation and apoptosis in UVA-irradiated human

erythroid cells in the presence of

furocoumarin derivatives

AUTHOR(S): Viola, Giampietro; Vedaldi, Daniela; Dall'Acqua,

Francesco; Fortunato, Elena; Basso, Giuseppe; Bianchi,

Nicoletta; Zuccato, Cristina; Borgatti, Monica; Lampronti, Ilaria; Gambari, Roberto

Department of Pharmaceutical Sciences, University of CORPORATE SOURCE:

Padova, Padua, 35131, Italy

SOURCE: Biochemical Pharmacology (2008), 75(4), 810-825

CODEN: BCPCA6; ISSN: 0006-2952

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

Psoralens, also known as furocoumarins, are a class of photosensitizers largely used in the therapy of various skin diseases. In this study we have evaluated the combined effects of UVA irradiation and furocoumarins derivs. on (a) erythroid differentiation and apoptosis of human leukemia K562 cells and (b) globin gene expression in cultures of human erythroid progenitors derived from the peripheral blood. To prove the activity of a series of linear and angular furocoumarins derivs., we employed the human leukemia K562 cell line and the two-phase liquid culture procedure for growing erythroid progenitors. Quant. real-time reverse transcription polymerase-chain assay (Q-RT-PCR) was employed for quantification of the accumulation of globin mRNAs. The results obtained demonstrate that both linear and angular furocoumarins are strong inducers of erythroid differentiation of K562 cells. From a preliminary screening, we have selected two derivs., 5-methoxypsoralen (5-MOP) and trimethylangelicin (TMA), for which we have investigated their mechanism of action. The cell cycle anal. showed that these derivs. induce, after irradiation, a cell

arrest in the G2/M phase, followed by apoptosis. Mitochondrial depolarization and caspases activation seem to be involved in the mechanism of cell death. In erythroid precursor cells, psoralens in combination with UVA irradiation, stimulate at very low concns. a preferential

increase of  $\gamma$ -globin mRNA. Altogether, these data suggest that psoralen derivs. warrant further evaluation as potential therapeutic drugs in  $\beta$ - thalassemia and sickle cell anemia.

523-50-2, Angelicin 4063-41-6 ΙT

> RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) ( $\gamma$ -globin mRNA, cell differentiation and apoptosis in UVA-irradiated human erythroid cells in presence of furocoumarin derivs.)

RN 523-50-2 CAPLUS

CN 2H-Furo[2,3-h]-1-benzopyran-2-one (CA INDEX NAME)

4063-41-6 CAPLUS RN

CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 4,8-dimethyl- (CA INDEX NAME)

THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 59 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:183297 CAPLUS

DOCUMENT NUMBER: 108:183297

108:30033a,30036a ORIGINAL REFERENCE NO.:

Method and kit for rapid detection of nucleic acid TITLE:

sequences in a sample by labeling the sample

Dattagupta, Nanibhushan; Rae, Peter M. M.; Rabin, INVENTOR(S):

Daniel U.; Huguenel, Edward D.

PATENT ASSIGNEE(S): Molecular Diagnostics, Inc., USA Eur. Pat. Appl., 29 pp.

SOURCE: CODEN: EPXXDW

Patent

DOCUMENT TYPE: LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 235726	A2	19870909	EP 1987-102577	19870224
EP 235726	A3	19890510		
EP 235726	B1	19930519		
R: AT, BE, CH,	DE, ES	, FR, GB, GF	R, IT, LI, NL, SE	
NO 8700613	A	19870907	NO 1987-613	19870217

CA 1295535	С	19920211	CA 1987-530235		19870220
AT 89606	T	19930615	AT 1987-102577		19870224
FI 8700923	A	19870906	FI 1987-923		19870303
DK 8701120	A	19870906	DK 1987-1120		19870304
ZA 8701554	A	19871230	ZA 1987-1554		19870304
AU 8769723	A	19870910	AU 1987-69723		19870305
AU 599083	B2	19900712			
JP 62265999	A	19871118	JP 1987-51169		19870305
CA 1314794	С	19930323	CA 1987-553597		19871204
US 5348855	A	19940920	US 1991-772625		19911004
PRIORITY APPLN. INFO.:			US 1986-836378	A	19860305
			US 1986-943006	А	19861229
			EP 1987-102577	А	19870224
			US 1987-24643	A	19870311

AΒ A method for detecting ≥1 microorganism or polynucleotide sequence from eukaryotic sources in a nucleic acid-containing sample comprises (a) labeling the nucleic acids in the test sample; (b) immobilizing an oligonucleotide or a single-stranded nucleic acid of ≥1 known microorganism or sequences from eukaryotic sources to make  $\geq 1$ probe; (c) contacting, under hybridization conditions, the labeled single-stranded sample nucleic acid and the immobilized probe to form a hybridized labeled nucleic acid; and (d) assaying for the hybridized nucleic acid by detecting the label. A kit comprises immobilized probe, reagent for labeling the sample nucleic acids, reagent for denaturing the nucleic acids, and hybridization reagents. Urine samples from patients with suspected urinary tract infections were centrifuged, treated with NaOH, and heated to  $1\bar{0}0^{\circ}$  to lyse the cells. The suspension was diluted with Na borate buffer and neutralized to pH 7. Biotin-PEGangelicin (preparation described) was added and the mixture was irradiated with a long-wavelength UV lamp for 15 min. The irradiated sample was added to hybridization reagents and hybridization was conducted with probes (whole genomic DNA of Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, etc.) immobilized onto nitrocellulose paper. Hybridization was detected by an immunogold assay with affinity-isolated goat anti-biotin antibody and Ag enhancement. A spot of human DNA was also present on the paper for detection of leukocytes.


ΙT 523-50-2, Angelicin

RL: ANST (Analytical study)

(labeling of cellular DNA with)

523-50-2 CAPLUS RN

2H-Furo[2,3-h]-1-benzopyran-2-one (CA INDEX NAME) CN



ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:850726 CAPLUS

TITLE: Furocoumarins photolysis products induce differentiation of human erythroid cells

AUTHOR(S): Viola, Giampietro; Vedaldi, Daniela; Dall'Acqua, Francesco; Lampronti, Ilaria; Bianchi, Nicoletta;

Zuccato, Cristina; Borgatti, Monica; Gambari, Roberto Department of Pharmaceutical Sciences, University of

CORPORATE SOURCE: Padova, Via Marzolo 5, University of Padova, Padua,

35131, Italy

Journal of Photochemistry and Photobiology, B: Biology SOURCE:

(2008), 92(1), 24-28 CODEN: JPPBEG; ISSN: 1011-1344

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

the

AB Psoralens, also known as furocoumarins, are a well-known class of photosensitizers largely used in the therapy of various skin disease. In this study we have evaluated the effects of crude pre-irradiated solns. of furocoumarins derivs. on (a) erythroid differentiation and apoptosis of human leukemic K562 cells and (b) Hb synthesis in cultures of human erythroid progenitors derived from the peripheral blood. To prove the activity of a mixture of photoproducts generated by UVA irradiation of

three psoralen derivs. 5-methoxypsoralen (5-MOP) 8-methoxypsoralen (8-MOP), and angelicin (ANG), we employed the human leukemic K562 cell line and the two-phase liquid culture procedure for growing erythroid progenitors. The results obtained demonstrate that pre-irradiated solns. of psoralen derivs. significantly induce erythroid differentiation of K562 cells irresp. of the type of derivative used, suggesting that the active photoproduct(s) share a common structure. Interestingly, solns. of psoralens irradiated in anaerobic conditions do not exhibits erythroid inducing ability, indicating that the effect is mostly due to photooxidized psoralen products. In erythroid precursor cells, psoralens photolysis products stimulates at low concns. an increase of Hb A and Hb F. Altogether, these data suggest that photoproducts of psoralen warrant further evaluation as potential therapeutic drugs in  $\beta$ - thalassemia and sickle cell anemia.

L9 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:164418 CAPLUS

DOCUMENT NUMBER: 108:164418

ORIGINAL REFERENCE NO.: 108:26955a,26958a

TITLE:

TITLE: Preparation and use of reagents for a single probe solution-phase hybridization assay for the detection of a nucleotide sequence, and kits containing the

reagents

INVENTOR(S): Dattagupta, Nanibhushan

PATENT ASSIGNEE(S): Molecular Diagnostics, Inc., USA

SOURCE: Eur. Pat. Appl., 50 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 237833 EP 237833 EP 237833	A2 A3 B1	19870923 19910116 19930113	EP 1987-102576	· <del></del>	19870224
R: AT, BE, CH,	•		R, IT, LI, NL, SE		
CA 1290664	C	19911015	CA 1986-526423		19861229
NO 8700612	A	19870907	NO 1987-612		19870217
AT 84574	T	19930115	AT 1987-102576		19870224
ES 2053457	Т3	19940801	ES 1987-102576		19870224
FI 8700922	A	19870906	FI 1987-922		19870303
DK 8701121	A	19870906	DK 1987-1121		19870304
ZA 8701555	A	19871125	ZA 1987-1555		19870304
AU 8769724	A	19870910	AU 1987-69724		19870305
JP 62282599	A	19871208	JP 1987-51170		19870305
US 4968602	A	19901106	US 1989-442423		19891121
PRIORITY APPLN. INFO.:			US 1986-836360	Α	19860305
			US 1986-927613	A	19861114
			EP 1987-102576	A	19870224

AB A particular nucleic acid sequence of clin. significance can be rapidly determined by a homogeneous single-probe hybridization assay. The test sample

containing chemical modified nucleic acids having a label (or a reactive site)

will hybridize with a nucleic acid probe carrying a reactive site (or a

label). The hybrids are selectively separated out by contacting then with

an

immobilized reactive partner. The hybrid and the reactive partner form a stable bond, and the extent of hybridization can be measured by determining

the

label in the immobilized fraction or a decrease in the label in the remaining solution. The homogeneous single-probe hybridization method, as described above was employed to detect the presence of  $\alpha-$  thalassemia in prenatal samples (no data). The sample nucleic acid and the probe were labeled photochem. With biotin and 4'-aminomethyl-4,5' di-Me angelicin, resp.

IT 80500-62-5P, 4'-Aminomethyl-4,5' dimethyl angelicin RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as hybridization probe)

RN 80500-62-5 CAPLUS

CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 9-(aminomethyl)-4,8-dimethyl- (CA INDEX NAME)

L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:550062 CAPLUS

DOCUMENT NUMBER: 111:150062

ORIGINAL REFERENCE NO.: 111:24949a,24952a

TITLE: Nucleic acid sequence determination by hybridization

probe and its use in the identification of

microorganisms and prokaryotic or eukaryotic DNA and

in clinical diagnosis

INVENTOR(S): Dattagupta, Nanibhushan; Rabin, Daniel; Rae, Peter;

Huguenel, Edward

PATENT ASSIGNEE(S): Molecular Diagnostics, Inc., USA

SOURCE: Eur. Pat. Appl., 31 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 281927 EP 281927	A2 A3	19880914 19910417	EP 1988-103221	19880303
EP 281927	B1	19950628		
R: CH, DE, ES,	FR, GB	, GR, IT, LI	, NL, SE	
CA 1314794	С	19930323	CA 1987-553597	19871204
AU 8812151	A	19880915	AU 1988-12151	19880223
AU 601021	В2	19900830		
JP 63313598	A	19881221	JP 1988-56517	19880311
US 5348855	A	19940920	US 1991-772625	19911004
PRIORITY APPLN. INFO.:			US 1987-24643	A 19870311
			US 1986-836378	B2 19860305
			US 1986-943006	A 19861229

AB A method for the detection and identification of microorganisms or nucleic acid sequences in a test sample comprises: (1) labeling the nucleic acids in the sample, (2) contacting the labeled nucleic acids with ≥1

immobilized probe containing complementary nucleic acids under hybridization conditions, and (3) detecting the label. The labeling compound 4'-biotinyl-PEG-4,5'-dimethylangelicin (I) was prepared In  $\alpha$ thalassemia diagnosis, a test sample containing nucleic acid was dissolved in 10 mM borate buffer (pH 8.0) to a final concentration of .apprx.20

 $\mu g/mL$ . To the nucleic acid solution I in aqueous solution was added to a final

concentration of 10  $\mu$ g/mL. The mixture was then irradiated at long wavelength

irradiation for .apprx.60 min using a black ray UVL 56 lamp. The labeled test

sample was hybridized with probes immobilized on a nitrocellulose strip at  $42^{\circ}$  for 16 h and the biotinylated hybrids were detected by a colorimetric or chemiluminescence method.

ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

2002:638196 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 137:165813

TITLE: Methods and compositions for analyzing nucleic acids

INVENTOR(S): Dattagupta, Nanibhushan

PATENT ASSIGNEE(S):

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION: DAMENIM NO

PAT	PATENT NO.				KIND DATE			APPLICATION NO.						DATE			
	2002		074		A1 B2		2002	– –	US 2001-791030						20010220		
WO	2002	0707			A2 A3		20020912 20070531			WO 2002-US3782					20020205		
0	W:	AE, CO, GM, LS, PL, UA, GH,	AG, CR, HR, LT, PT, UG, GM,	CU, HU, LU, RO, UZ, KE,	AM, CZ, ID, LV, RU, VN, LS,	AT, DE, IL, MA, SD, YU, MW,	AU, DK, IN, MD, SE, ZA, MZ,	AZ, DM, IS, MG, SG, ZW SD,	DZ, JP, MK, SI,	EC, KE, MN, SK,	EE, KG, MW, SL,	ES, KP, MX, TJ,	FI, KR, MZ, TM,	GB, KZ, NO, TN,	GD, LC, NZ, TR,	GE, LK, OM, TT,	GH, LR, PH, TZ,
_	2002: 2003: APP:	BF, AP, 3117.	BJ, EA, 59	CF, AM,	CG, AZ, A1	CI, BY,	FR, CM, KG, 2002	GA, KZ, 0919	GN, MD,	GQ,	GW, TJ, 002-	ML, TM, 3117.	MR, EP, 59	NE, OA	SN, 2 2	SE, TD, 0020: 0030: 0010:	TG, 205 609
										WO 2	002-	US37	82	1	w 2	0020	205

The present invention relates to methods and compns. for analyzing nucleic AΒ acids. In particular, the invention provides for methods and combinations for analyzing nucleic acids in a plurality of samples using a plurality of detectably different signature labels and a probe that is hybridizable to each of the target nucleic acids. The invention also provides for a method for quantifying a nucleic acid by analyzing the amount of a label, e.g., a photoactivatable label, attached to the target nucleic acid.

80500-62-5P, 4'-Aminomethyl-4,5'-dimethyl angelicin ΙT RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)

(methods and compns. for analyzing nucleic acids)

RN 80500-62-5 CAPLUS

2H-Furo[2,3-h]-1-benzopyran-2-one, 9-(aminomethyl)-4,8-dimethyl- (CA CN INDEX NAME)

L9 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:56598 CAPLUS

DOCUMENT NUMBER: 116:56598

ORIGINAL REFERENCE NO.: 116:9751a,9754a

TITLE: Defective DNA endonuclease activities in Fanconi's

anemia cells, complementation groups A and B

AUTHOR(S): Lambert, Muriel W.; Tsongalis, Gregory J.; Lambert, W.

Clark; Hang, Bo; Parrish, David D.

CORPORATE SOURCE: New Jersey Med. Sch., UMDNJ, Newark, NJ, 07103, USA

SOURCE: Mutation Research, DNA Repair (1991), 273(1), 57-71

CODEN: MRDRBE; ISSN: 0921-8777

DOCUMENT TYPE: Journal LANGUAGE: English

Cells from patients with the inherited disorder, Fanconi's anemia (FA), were analyzed for endonucleases which recognize DNA interstrand cross-links and monoadducts produced by psoralen plus UVA irradiation Two chromatin-associated DNA endonuclease activities, defective in their ability to incise DNA-containing adducts produced by psoralen plus UVA light, have been identified and isolated in nuclei of FA cells. In FA complementation group A (FA-A) cells, one endonuclease activity, pI 4.6, which recognizes psoralen intercalation and interstrand cross-links, has 25% of the activity of the normal human endonuclease, pI 4.6, on 8-methoxypsoralen (8-MOP) plus UVA-damaged DNA. In FA complementation group B (FA-B) cells, a second endonuclease activity, pI 7.6, which recognizes psoralen monoadducts, has 50% and 55% of the activity, resp., of the corresponding normal endonuclease on 8-MOP or angelicin plus UVA-damaged DNA. Kinetic anal. reveals that both the FA-A endonuclease activity, pI 4.6, and the FA-B endonuclease activity, pI 7.6, have decreased affinity for psoralen plus UVA-damaged DNA. Both the normal and FA endonucleases showed .apprx.2.5-fold increase in activity on psoralen plus UVA-damaged reconstituted nucleosomal DNA compared to damaged non-nucleosomal DNA, indicating that interaction of these FA endonucleases with nucleosomal DNA is not impaired. These deficiencies in two nuclear DNA endonuclease activities from FA-A nd FA-B cells correlate with decreased levels of unscheduled DNA synthesis (UDS), in response to 8-MOP or angelicin plus UVA irradiation, in these cells in culture.